Publications by authors named "Shawn D Doran"

Claim this Profile
F
First-in-Human Evaluation of F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B.
Yuichi Wakabayashi, Per Stenkrona, Ryosuke Arakawa, Xuefeng Yan, Maia G Van Buskirk, Shawn D Doran

J Nucl Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
Kim Huard, Aaron C Smith, Gregg Cappon, Robert L Dow, David J Edmonds, Shawn D Doran

J Med Chem· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Analysis of F-PF-06684511, a Novel PET Radioligand for Selective β-Secretase 1 Imaging, in Nonhuman Primate Brain.
Akihiro Takano, Laigao Chen, Sangram Nag, Michael A Brodney, Ryosuke Arakawa, Shawn D Doran

J Nucl Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.
Brian T O'Neill, Elizabeth M Beck, Christopher R Butler, Charles E Nolan, Cathleen Gonzales, Shawn D Doran

J Med Chem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain.
Lei Zhang, Laigao Chen, Jason K Dutra, Elizabeth M Beck, Sangram Nag, Shawn D Doran

J Med Chem· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189.
Antonia F Stepan, Tuan P Tran, Christopher J Helal, Maria S Brown, Cheng Chang, Shawn D Doran

ACS Med Chem Lett· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) Imaging.
Lei Zhang, Laigao Chen, Elizabeth M Beck, Thomas A Chappie, Richard V Coelho, Shawn D Doran

J Med Chem· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors.
Andrea M Zuhl, Charles E Nolan, Michael A Brodney, Sherry Niessen, Kevin Atchison, Shawn D Doran

Nat Commun· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of spirocyclic-diamine inhibitors of mammalian acetyl CoA-carboxylase.
Daniel W Kung, David A Griffith, William P Esler, Felix F Vajdos, Alan M Mathiowetz, Shawn D Doran

Bioorg Med Chem Lett· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.
Michael A Brodney, Elizabeth M Beck, Christopher R Butler, Gabriela Barreiro, Eric F Johnson, Shawn D Doran

J Med Chem· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.
Christopher R Butler, Michael A Brodney, Elizabeth M Beck, Gabriela Barreiro, Charles E Nolan, Shawn D Doran

J Med Chem· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes.
David A Griffith, Daniel W Kung, William P Esler, Paul A Amor, Scott W Bagley, Shawn D Doran

J Med Chem· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.
David A Griffith, Robert L Dow, Kim Huard, David J Edmonds, Scott W Bagley, Shawn D Doran

J Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
Raman Sharma, Hao Sun, David W Piotrowski, Tim F Ryder, Shawn D Doran

Drug Metab Dispos· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of triazolopyrimidine-based PDE8B inhibitors: exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes.
Michael P DeNinno, Stephen W Wright, John B Etienne, Thanh V Olson, Benjamin N Rocke, Shawn D Doran

Bioorg Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase.
Kevin D Freeman-Cook, Paul Amor, Scott Bader, Leanne M Buzon, Steven B Coffey, Shawn D Doran

J Med Chem· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1,5-Substituted nipecotic amides: selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability.
Michael P DeNinno, Stephen W Wright, Michael S Visser, John B Etienne, Dianna E Moore, Shawn D Doran

Bioorg Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.
Kim M Andrews, David A Beebe, John W Benbow, David A Boyer, Shawn D Doran

Bioorg Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2.
Jeffrey W Corbett, Kevin D Freeman-Cook, Richard Elliott, Felix Vajdos, Francis Rajamohan, Shawn D Doran

Bioorg Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists.
Paul S Humphries, John W Benbow, Paul D Bonin, David Boyer, Shawn D Doran

Bioorg Med Chem Lett· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
Mark J Ammirati, Kim M Andrews, David D Boyer, Anne M Brodeur, Dennis E Danley, Shawn D Doran

Bioorg Med Chem Lett· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
Stephen W Wright, Mark J Ammirati, Kim M Andrews, Anne M Brodeur, Dennis E Danley, Shawn D Doran

Bioorg Med Chem Lett· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration.
Xingrong Liu, Bill J Smith, Cuiping Chen, Ernesto Callegari, Stacey L Becker, Angela C Doran, Shawn D Doran

Drug Metab Dispos· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.
Stephen W Wright, Mark J Ammirati, Kim M Andrews, Anne M Brodeur, Dennis E Danley, Shawn D Doran

J Med Chem· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding.
Xingrong Liu, Bill J Smith, Cuiping Chen, Ernesto Callegari, Stacey L Becker, Angela C Doran, Shawn D Doran

J Pharmacol Exp Ther· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis